New hope for Hard-to-Treat myeloma: teclistamab trial in japan
NCT ID NCT04696809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested teclistamab, a drug that helps the immune system find and attack myeloma cells, in 40 Japanese patients whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and find the right dose in phase 1, then see how well it works in phase 2. The trial is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teclistamab (a bispecific antibody that helps immune cells attack myeloma cells)
What this could lead to
If successful, this could provide a new treatment option for Japanese patients with multiple myeloma that has returned or not responded to other therapies.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to all patients. Side effects like cytokine release syndrome and other immune reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Japanese Red Cross Medical Center
Shibuya City, 150-8935, Japan
-
Japanese Red Cross Osaka Hospital
Osaka, 543-8555, Japan
-
Kameda Medical Center
Chiba, 296-8602, Japan
-
Kobe City Medical Center General Hospital
Kobe, 650 0047, Japan
-
Kurume University Hospital
Kurume, 830-0011, Japan
-
Kyoto Kuramaguchi Medical Center
Kyoto, 603-8151, Japan
-
Nagoya City University Hospital
Nagoya, 467 8602, Japan
-
National Hospital Organization Hiroshima-Nishi Medical Center
Ōtake, 739-0696, Japan
-
National Hospital Organization Kumamoto Medical Center
Kumamoto, 860-0008, Japan
-
National Hospital Organization Matsumoto Medical Center
Matsumoto, 399-8701, Japan
-
National Hospital Organization Mito Medical Center
Higashiibaraki-gun, 311-3193, Japan
-
National Hospital Organization Okayama Medical Center
Okayama, 701-1192, Japan
-
Niigata Cancer Center Hospital
Niigata, 951-8566, Japan
-
Ogaki Municipal Hospital
Gifu, 503-8502, Japan
-
Osaka International Cancer Institute
Osaka, 541 8567, Japan